Medical Market Report

Global Anti-malarial Drugs Market By Type (Quinine, Chloroquine, Pyrimethamine, Amodiaquine, Proguanil, Mefloquine, Sulfonamide, and Other), By Application (Falciparum Malaria, Vivax Malaria, and Others), By Region, and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2020-2029

  • 137906
  • 18-Dec
  • PDF/PPT/Word
  • ★ ★ ★ ★ ★
    ★ ★ ★ ★ ★
  • Report Details

    Global Anti-malarial Drugs Market is estimated to be valued US$ XX.X million in 2019. The report on Anti-malarial Drugs Market provides qualitative as well as quantitative analysis in terms of market dynamics, competition scenarios, opportunity analysis, market growth, etc. for the forecast year up to 2029. The global anti-malarial drugs market is segmented on the basis of Type, Application, and geography.

    Europe market was valued at US$ XX.X million in 2018 and is projected to reach US$ XX.X million in 2029, and register a CAGR of X.X% during the forecast period, according to a new Market.us (Prudour Research) study.

    Anti-malarial Drugs Market Scope:

    By type, the market is segmented into Quinine, Chloroquine, Pyrimethamine, Amodiaquine, Proguanil, Mefloquine, Sulfonamide, and Other. By Application, the market is divided into Falciparum Malaria, Vivax Malaria, and Others.
    Based on geography, the market is analyzed across North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. Major players profiled in the report include Merck KGaA, F. Hoffmann-La Roche AG, Novartis AG, GlaxoSmithKline Plc, Ranbaxy Laboratories, Zydus Cadila, Alvizia Health Care, Bayer AG, Pfizer, and Ipca Laboratories Ltd.

    Key Market Segments

    Type

    Quinine

    Chloroquine

    Pyrimethamine

    Amodiaquine

    Proguanil

    Mefloquine

    Sulfonamide

    Other

    Application

    Falciparum Malaria

    Vivax Malaria

    Others

    Key Market Players included in the report:

    Merck KGaA

    F. Hoffmann-La Roche AG

    Novartis AG

    GlaxoSmithKline Plc

    Ranbaxy Laboratories

    Zydus Cadila

    Alvizia Health Care

    Bayer AG

    Pfizer

    Ipca Laboratories Ltd

    Reasons to Get this Report:

    In an insight outlook, this research report has dedicated to several quantities of analysis – industry research (global industry trends) and Anti-malarial Drugs Market share analysis of high players, along with company profiles, and which collectively include about the fundamental opinions regarding the market landscape; emerging and high-growth sections of Anti-malarial Drugs Market; high-growth regions; and market drivers, restraints, and also market chances.
    The analysis covers Anti-malarial Drugs Market and its advancements across different industry verticals as well as regions. It targets estimating the current market size and growth potential of the global Anti-malarial Drugs Market across sections such as also Application and representatives.
    Additionally, the analysis also has a comprehensive review of the crucial players on the Anti-malarial Drugs Market together side their company profiles, SWOT analysis, latest advancements, and business plans.

    The analysis objectives of the report are:

    To equitably share in-depth info regarding the crucial elements impacting the increase of industry (growth capacity, chances, drivers, and industry-specific challenges and risks).
    To know the Anti-malarial Drugs Market by pinpointing its many subsegments.
    To profile the important players and analyze their growth plans.
    To endeavor the amount and value of Anti-malarial Drugs sub-markets, depending on key regions (various vital states).
    To analyze Anti-malarial Drugs Market concerning growth trends, prospects, and also their participation in the entire sector.
    To examine and study the Anti-malarial Drugs Market size (volume & value) from the company, essential regions/countries, products, and Application, background information from 2013 to 2018, and also prediction to 2029.
    Primary worldwide Anti-malarial Drugs Market manufacturing companies, to specify, clarify and analyze the product sales amount, value and market share, market rivalry landscape, SWOT analysis and development plans next coming years.
    To examine competitive progress such as expansions, arrangements, new product launches, and acquisitions on the market.

  • Table Of Content 
    1. Anti-malarial Drugs Market Introduction
    

    1.1. Definition
    
1.2. Taxonomy
    
1.3. Research Scope2. Executive Summary
    

      2.1. Key Findings by Major Segments
    
  2.2. Top strategies by Major Players3. Global Anti-malarial Drugs Market Overview
    

    3.1. Anti-malarial Drugs Market Dynamics
    

        3.1.1. Drivers
    
    3.1.2. Opportunities
    
    3.1.3. Restraints
    
    3.1.4. Challenges  3.2. PESTLE Analysis
    
  3.3. Opportunity Map Analysis
    
  3.4. PORTER’S Five Forces Analysis
    
  3.5. Market Competition Scenario Analysis
    
  3.6. Product Life Cycle Analysis
    
  3.7. Opportunity Orbits
    
  3.8. Production Analysis by Region/Company
    
  3.9. Industry chain Analysis
    
  3.10. Marketing Strategy4. Global Anti-malarial Drugs Market Value & Volume ((US$ Mn & ‘000 Units)), Share (%), and Growth Rate (%) Comparison by Type, 2012-2028
    

      4.1. Global Anti-malarial Drugs Market Analysis by Type: Introduction
    
  4.2. Market Size and Forecast by Region
    
  4.3. Quinine
    

      4.4. Chloroquine
    

      4.5. Pyrimethamine
    

      4.6. Amodiaquine
    

      4.7. Proguanil
    

      4.8. Mefloquine
    

      4.9. Sulfonamide
    

      4.10. Other5. Global Anti-malarial Drugs Market Value & Volume ((US$ Mn & ‘000 Units)), Share (%), and Growth Rate (%) Comparison by Application, 2012-2028
    

      5.1. Global Anti-malarial Drugs Market Analysis by Application: Introduction
    
  5.2. Market Size and Forecast by Region
    
  5.3. Falciparum Malaria
    

      5.4. Vivax Malaria
    

      5.5. Others6. Global Anti-malarial Drugs Market Value & Volume ((US$ Mn & ‘000 Units)), Share (%), and Growth Rate (%) Comparison by Region, 2012-2028
    

      6.1. North America
    

        6.1.1. North America Anti-malarial Drugs Market: Regional Trend Analysis
    

         6.1.1.1. US
    
     6.1.1.2. Canada
    
     6.1.1.3. Mexico
    

      6.2.1. Europe
    

        6.2.1. Europe Anti-malarial Drugs Market: Regional Trend Analysis
    

         6.2.1.1. Germany
    
     6.2.1.2. France
    
     6.2.1.3. UK
    
     6.2.1.4. Russia
    
     6.2.1.5. Italy
    
     6.2.1.6. Spain
    
     6.2.1.7. Rest of Europe
    

      6.3. Asia-Pacific
    

        6.3.1. Asia-Pacific Anti-malarial Drugs Market: Regional Trend Analysis
    

         6.3.1.1. China
    
     6.3.1.2. Japan
    
     6.3.1.3. Korea
    
     6.3.1.4. India
    
     6.3.1.5. Rest of Asia-Pacific
    

      6.4. Latin America
    

        6.4.1. Latin America Anti-malarial Drugs Market: Regional Trend Analysis
    

         6.4.1.1. Brazil
    
     6.4.1.2. Argentina
    
     6.4.1.3. Rest of Latin America
    

      6.5. Middle East and Africa
    

        6.5.1. Middle East and Africa Anti-malarial Drugs Market: Regional Trend Analysis
    

         6.5.1.1. GCC
    
     6.5.1.2. South Africa
    
     6.5.1.3. Israel
    
     6.5.1.4. Rest of MEA
    
7. Global Anti-malarial Drugs Market Competitive Landscape, Market Share Analysis, and Company Profiles
    

      7.1. Market Share Analysis
    
  7.2. Company Profiles
    
  7.3. Merck KGaA
    

        7.3.1. Company Overview
    
    7.3.2. Financial Highlights
    
    7.3.3. Product Portfolio
    
    7.3.4. SWOT Analysis
    
    7.3.5. Key Strategies and Developments  7.4. F. Hoffmann-La Roche AG
    

        7.4.1. Company Overview
    
    7.4.2. Financial Highlights
    
    7.4.3. Product Portfolio
    
    7.4.4. SWOT Analysis
    
    7.4.5. Key Strategies and Developments  7.5. Novartis AG
    

        7.5.1. Company Overview
    
    7.5.2. Financial Highlights
    
    7.5.3. Product Portfolio
    
    7.5.4. SWOT Analysis
    
    7.5.5. Key Strategies and Developments  7.6. GlaxoSmithKline Plc
    

        7.6.1. Company Overview
    
    7.6.2. Financial Highlights
    
    7.6.3. Product Portfolio
    
    7.6.4. SWOT Analysis
    
    7.6.5. Key Strategies and Developments  7.7. Ranbaxy Laboratories
    

        7.7.1. Company Overview
    
    7.7.2. Financial Highlights
    
    7.7.3. Product Portfolio
    
    7.7.4. SWOT Analysis
    
    7.7.5. Key Strategies and Developments  7.8. Zydus Cadila
    

        7.8.1. Company Overview
    
    7.8.2. Financial Highlights
    
    7.8.3. Product Portfolio
    
    7.8.4. SWOT Analysis
    
    7.8.5. Key Strategies and Developments  7.9. Alvizia Health Care
    

        7.9.1. Company Overview
    
    7.9.2. Financial Highlights
    
    7.9.3. Product Portfolio
    
    7.9.4. SWOT Analysis
    
    7.9.5. Key Strategies and Developments  7.10. Bayer AG
    

        7.10.1. Company Overview
    
    7.10.2. Financial Highlights
    
    7.10.3. Product Portfolio
    
    7.10.4. SWOT Analysis
    
    7.10.5. Key Strategies and Developments  7.11. Pfizer
    

        7.11.1. Company Overview
    
    7.11.2. Financial Highlights
    
    7.11.3. Product Portfolio
    
    7.11.4. SWOT Analysis
    
    7.11.5. Key Strategies and Developments  7.12. Ipca Laboratories Ltd
    

        7.12.1. Company Overview
    
    7.12.2. Financial Highlights
    
    7.12.3. Product Portfolio
    
    7.12.4. SWOT Analysis
    
    7.12.5. Key Strategies and Developments
    

    8. Assumptions and Acronyms
    
9. Research Methodology
    
10. Contact
  • Inquiry Before Buying

    Inquiry Form

  • Request Sample

    Request for Sample

Related Reports

Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.